Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Kim, Jeeyong | - |
dc.contributor.author | Cho, Yunjung | - |
dc.contributor.author | Seo, Bo Kyoung | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.date.available | 2020-11-03T12:44:45Z | - |
dc.date.issued | 2007-05 | - |
dc.identifier.issn | 0368-2811 | - |
dc.identifier.issn | 1465-3621 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/17969 | - |
dc.description.abstract | Plasma cell leukemia is a rare malignant plasma cell disorder characterized by proliferation of plasma cells in blood and the bone marrow, the outcome of which is poor with conventional therapy. More effective treatment strategies are therefore needed for this disorder. Here, we report a case of secondary plasma cell leukemia from Immunoglobulin D multiple myeloma refractory to doxorubicin-containing chemotherapy and thalidomide. The patient achieved complete remission with bortezomib-containing chemotherapy as follows: bortezomib 1.3 mg/m(2) intravenous infusion on days 1, 4, 8 and 11; cyclophosphamide 750 Mg/M-2 intravenous infusion on days 1 and 3; dexamethasone 40 mg/m(2) intravenous infusion on days 1-4. Complete remission was maintained until the fourth course of the treatment, and we then performed autologous peripheral blood stem cell transplantation. Our experience suggests that combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be an effective induction treatment for plasma cell leukemia. | - |
dc.format.extent | 3 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | OXFORD UNIV PRESS | - |
dc.title | Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1093/jjco/hym037 | - |
dc.identifier.scopusid | 2-s2.0-34547869650 | - |
dc.identifier.wosid | 000248688100009 | - |
dc.identifier.bibliographicCitation | JAPANESE JOURNAL OF CLINICAL ONCOLOGY, v.37, no.5, pp 382 - 384 | - |
dc.citation.title | JAPANESE JOURNAL OF CLINICAL ONCOLOGY | - |
dc.citation.volume | 37 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 382 | - |
dc.citation.endPage | 384 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.subject.keywordPlus | MULTIPLE-MYELOMA | - |
dc.subject.keywordAuthor | bortezomib | - |
dc.subject.keywordAuthor | cyclophosphamide | - |
dc.subject.keywordAuthor | plasma cell leukemia | - |
dc.subject.keywordAuthor | multiple myeloma | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.